Allena Pharmaceuticals to Participate in H.C. Wainwright's 23rd Annual Global Investment Conference

NEWTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. ALNA, a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today announced that company management will virtually participate in H.C. Wainwright's 23rd Annual Global Investment Conference, being held September 13th – 15th, 2021.

Louis Brenner, M.D., Allena's President and Chief Executive Officer, will virtually participate in a fireside chat at the conference. The pre-recorded discussion will be available on demand beginning 7:00 a.m. ET on September 13th. A recording can also be accessed for 90 days at the link below or via the Allena Pharmaceuticals website within the Investors/Events and Presentations section.

Please see details for the session below:

Date:7:00 a.m. ET
Time:Monday, September 13th, 2021
Webcast:https://journey.ct.events/view/f1d0178c-8b66-4f9b-bbb4-f26ad0dc2801

Management will also be available for 1x1 meetings. If you would like to request a meeting, please email meetings@hcwco.com.

About Allena Pharmaceuticals



Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases. Allena's lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study recently completed and a Phase 2a program recently initiated.

Investor Contact

Ashley Robinson

LifeSci Advisors, LLC

617-430-7577

arr@lifesciadvisors.com

Media Contact

Adam Daley

Berry & Company Public Relations

212-253-8881

adaley@berrypr.com 



Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!